DRG Market Assessment 보고서

Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key soft tissue sarcoma patient populations, covering 171 countries and…

Clarivate Epidemiology’s coverage of soft tissue sarcoma (STS) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and…

Clarivate Epidemiology’s coverage of soft tissue sarcoma comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the diagnosed incidence and…

Chronic kidney disease (CKD) encompasses a set of heterogeneous disorders that gradually damage the kidneys’ structure or function. To manage CKD and delay its progression to end-stage kidney…

Chronic kidney disease (CKD) encompasses a set of heterogeneous disorders that gradually damage the kidneys’ structure or function. To manage CKD and delay its progression to end-stage kidney…

Clarivate Epidemiology’s coverage of thyroid cancer comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the diagnosed incidence and diagnosed…

Clarivate Epidemiology’s coverage of thyroid cancer comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of…

Clarivate’s extended worldwide coverage is the first and only evidence-based data set of epidemiological forecasts for key thyroid cancer patient populations covering 171 countries and more than…

The treatment of multiple myeloma is becoming increasingly complex. Sanofi’s Sarclisa received a label expansion for the first-line treatment of autologous stem-cell transplantation-ineligible…

Ever since Novartis’s Kymriah became the first chimeric antigen receptor (CAR) T-cell therapy approved by the FDA for a cancer indication (acute lymphoblastic leukemia) in 2017, this class of…

Migraine, which afflicts approximately 73 million people in the major pharmaceutical markets according to Clarivate Epidemiology, is a heterogeneous condition requiring individualized treatment…

Several new brands have recently entered the competitive Parkinson’s disease (PD) therapy market, including AbbVie’s Vyalev / Produodopa / Scyova (foslevodopa / foscarbidopa subcutaneous pump…